Benign Prostatic Hyperplasia: Symptoms, Causes & Treatment

Benign prostatic hyperplasia (BPH) is the most common benign tumor in men and one of the most prevalent age-related conditions worldwide, affecting approximately 50% of men in their 60s and up to 90% by age 80. The prostate gland lies immediately below the bladder and encircles the proximal urethra; as it enlarges — predominantly in the transition zone — it compresses the urethra and impedes urine flow, producing the spectrum of lower urinary tract symptoms (LUTS) that characterizes BPH.

Pathogenesis involves androgen-driven hyperplasia: dihydrotestosterone (DHT), derived from testosterone by 5-alpha-reductase, stimulates proliferation of stromal and epithelial cells. Increased smooth muscle tone in the prostate and bladder neck — mediated by alpha-1 adrenergic receptors — further contributes to dynamic obstruction. While BPH is entirely benign and histologically unrelated to prostate cancer, its symptoms significantly impair sleep, quality of life, and daily functioning.

The International Prostate Symptom Score (IPSS) standardizes symptom severity assessment. Treatments include watchful waiting for mild disease, alpha-1 blockers and 5-alpha-reductase inhibitors for medical management, and minimally invasive or surgical options (TURP being the gold standard) for refractory or complicated cases including urinary retention.

• Weak, slow, or intermittent urinary stream
• Hesitancy, straining, and prolonged time to initiate voiding
• Nocturia (waking two or more times per night to urinate)
• Urgency and urgency urinary incontinence
• Sensation of incomplete bladder emptying
• Acute urinary retention in advanced or decompensated cases

• Aging and associated hormonal changes (rising estrogen-to-testosterone ratio)
• Dihydrotestosterone (DHT) stimulating transition zone cell proliferation via 5-alpha-reductase
• Genetic predisposition: positive family history doubles risk
• Obesity and sedentary lifestyle
• Diabetes mellitus and metabolic syndrome

• Age Over 50: Risk increases significantly with each decade after 50 years old.
• Family History: Having a first-degree relative with BPH doubles your risk.
• Obesity: Being overweight is associated with increased risk of BPH.
• Diabetes: Men with diabetes are more prone to developing prostate symptoms.
• Physical Inactivity: Lack of regular exercise increases risk.
• Cardiovascular Disease: Heart and vascular conditions are linked to increased BPH risk.
• Certain Medications: SSRIs and other drugs may worsen symptoms.
• Recurrent Urinary Infections: History of UTIs may increase risk.

Diagnosis is based on IPSS symptom scoring, digital rectal examination (assessing gland size and consistency), urinalysis (to exclude infection or haematuria), serum PSA (to screen for prostate cancer), and post-void residual urine measurement by ultrasound. Uroflowmetry and pressure-flow studies are reserved for complex or surgical cases.

Management is stratified by symptom severity. Watchful waiting suits mild disease. Medical therapy: alpha-1 blockers (tamsulosin, alfuzosin) relax smooth muscle for immediate symptom relief; 5-alpha-reductase inhibitors (finasteride, dutasteride) shrink the gland over months — combination therapy is preferred for large prostates. Surgical options for refractory disease include transurethral resection of the prostate (TURP), holmium laser enucleation (HoLEP), Rezūm water-vapor therapy, and UroLift prostatic urethral lift.

• Acute and chronic urinary retention requiring catheterization
• Recurrent urinary tract infections due to incomplete bladder emptying
• Bladder stone formation
• Chronic kidney disease from sustained back-pressure (rare in untreated advanced cases)

• Regular aerobic exercise and weight management reduce LUTS severity
• Limit evening fluid intake, caffeine, and alcohol to reduce nocturia
• Regular screening after age 50 for early symptom detection and PSA monitoring